GlassScriptPhysician profile
Kuljit K Chima
NPI 1497794861
$4,732.98
in general payments reported to CMS, 2019-2025
31 companies · $1,812 in 2025
The $1,812 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $73.41 · 2021: $57.04 · 2022: $508 · 2023: $813 · 2024: $774 · 2025: $1,812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,200.58 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $540.35 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Biofrontera INC. | $515.82 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $401.28 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Janssen Biotech, INC. | $376.59 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $359.64 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $359.09 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $265.18 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $237.50 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $202.68 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $189.02 | 2019-2025 | Libtayo |
| Ucb, INC. | $144.79 | 2025 | Bimzelx |
| Leo Pharma INC. | $134.78 | 2019-2025 | Anzupgo |
| Lnhc, INC | $124.98 | 2025 | Zelsuvmi |
| Sun Pharmaceutical Industries INC. | $119.62 | 2019-2025 | Winlevi, Absorica Ld, Odomzo |
| Abbvie INC. | $106.45 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $99.70 | 2022 | |
| Genzyme Corporation | $92.63 | 2022-2024 | |
| Botanix Sb INC | $86.08 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $78.95 | 2019-2023 | |
| Pfizer INC. | $76.07 | 2020-2024 | |
| Genentech USA, INC. | $35.49 | 2021-2023 | Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2023-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $29.75 | 2025 | |
| Strata Skin Sciences, INC. | $20.23 | 2024 | Xtrac |
| Organon LLC | $19.66 | 2025 | Vtama |
| Blueprint Medicines Corporation | $15.10 | 2023 | Ayvakit |
| Journey Medical Corporation | $14.53 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.47 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $13.74 | 2022 | |
| Promius Pharma LLC | $13.35 | 2019 | |
| Celgene Corporation | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kuljit Chima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.